PFG Advisors Makes New $325,000 Investment in Cencora, Inc. $COR

PFG Advisors acquired a new position in Cencora, Inc. (NYSE:COR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,084 shares of the company’s stock, valued at approximately $325,000.

A number of other large investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Cencora in the 1st quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Cencora in the 1st quarter valued at $39,000. Hantz Financial Services Inc. grew its holdings in shares of Cencora by 712.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock valued at $61,000 after purchasing an additional 178 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Cencora during the 2nd quarter valued at $61,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,544 shares of company stock valued at $12,230,941 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Cencora Stock Down 0.4%

Shares of NYSE:COR opened at $363.75 on Thursday. The stock’s 50-day moving average is $318.52 and its 200 day moving average is $301.12. The company has a market cap of $70.52 billion, a PE ratio of 37.42, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $366.17.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the company earned $3.34 EPS. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group upped their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Mizuho boosted their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company lifted their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Robert W. Baird increased their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $371.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.